Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK137 in advanced malignant tumors
NCT06691360Phase 1Not yet recruiting
- Sponsor
- Akeso, Inc.
- Start
- Dec 2024
- Primary completion
- May 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AK137 in cancer, sponsored by Akeso, Inc. Primary endpoints: Adverse Events and Dose-Limiting Toxicity. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
AK137
03
Conditions
cancer
Beyond the preview
Go deeper on NCT06691360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06691360.